• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Other 1 o Market segments o Comparison by Other1 o Enteral - Market size and forecast 2019-2024 o Parenteral - Market size and forecast 2019-2024 o Topical - Market size and forecast 2019-2024 o Market opportunity by Other1 • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher priced units o Market challenges o Market trends • Vendor Landscape o Overview o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Bayer AG o F. Hoffmann-La Roche Ltd. o GlaxoSmithKline Plc o Johnson & Johnson o Merck & Co. Inc. o Novartis AG o Pfizer Inc. o Sanofi o Takeda Pharmaceutical Co. Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 5 • 5.Key Finding 6 • 6.Key Finding 7 • 7.Key Finding 8 • 8.Parent market • 9.Market characteristics • 10.Offerings of vendors included in the market definition • 11.Market segments • 12.Global - Market size and forecast 2019 - 2024 ($ billion) • 13.Global market: Year-over-year growth 2019 - 2024 (%) • 14.Five forces analysis 2019 & 2024 • 15.Bargaining power of buyers • 16.Bargaining power of suppliers • 17.Threat of new entrants • 18.Threat of substitutes • 19.Threat of rivalry • 20.Market condition - Five forces 2019 • 21.Other1 - Market share 2019-2024 (%) • 22.Comparison by Other1 • 23.Enteral - Market size and forecast 2019-2024 ($ billion) • 24.Enteral - Year-over-year growth 2019-2024 (%) • 25.Parenteral - Market size and forecast 2019-2024 ($ billion) • 26.Parenteral - Year-over-year growth 2019-2024 (%) • 27.Topical - Market size and forecast 2019-2024 ($ billion) • 28.Topical - Year-over-year growth 2019-2024 (%) • 29. Market opportunity by Other1 • 30.Customer landscape • 31.Market share by geography 2019-2024 (%) • 32.Geographic comparison • 33.North America - Market size and forecast 2019-2024 ($ billion) • 34.North America - Year-over-year growth 2019-2024 (%) • 35.Europe - Market size and forecast 2019-2024 ($ billion) • 36.Europe - Year-over-year growth 2019-2024 (%) • 37.Asia - Market size and forecast 2019-2024 ($ billion) • 38.Asia - Year-over-year growth 2019-2024 (%) • 39.ROW - Market size and forecast 2019-2024 ($ billion) • 40.ROW - Year-over-year growth 2019-2024 (%) • 41.Key leading countries • 42.Market opportunity by geography ($ billion) • 43.Impact of drivers and challenges • 44.Vendor landscape • 45.Landscape disruption • 46.Industry risks • 47.Vendors covered • 48.Market positioning of vendors • 49.AbbVie Inc. - Overview • 50.AbbVie Inc. - Business segments • 51.AbbVie Inc. - Key offerings • 52.AbbVie Inc. - Key customers • 53.AbbVie Inc. - Segment focus • 54.Bayer AG - Overview • 55.Bayer AG - Business segments • 56.Bayer AG - Key offerings • 57.Bayer AG - Key customers • 58.Bayer AG - Segment focus • 59.F. Hoffmann-La Roche Ltd. - Overview • 60.F. Hoffmann-La Roche Ltd. - Business segments • 61.F. Hoffmann-La Roche Ltd. - Key offerings • 62.F. Hoffmann-La Roche Ltd. - Key customers • 63.F. Hoffmann-La Roche Ltd. - Segment focus • 64.GlaxoSmithKline Plc - Overview • 65.GlaxoSmithKline Plc - Business segments • 66.GlaxoSmithKline Plc - Key offerings • 67.GlaxoSmithKline Plc - Key customers • 68.GlaxoSmithKline Plc - Segment focus • 69.Johnson & Johnson - Overview • 70.Johnson & Johnson - Business segments • 71.Johnson & Johnson - Key offerings • 72.Johnson & Johnson - Key customers • 73.Johnson & Johnson - Segment focus • 74.Merck & Co. Inc. - Overview • 75.Merck & Co. Inc. - Product and service • 76.Merck & Co. Inc. - Key offerings • 77.Merck & Co. Inc. - Key customers • 78.Merck & Co. Inc. - Segment focus • 79.Novartis AG - Overview • 80.Novartis AG - Business segments • 81.Novartis AG - Key offerings • 82.Novartis AG - Key customers • 83.Novartis AG - Segment focus • 84.Pfizer Inc. - Overview • 85.Pfizer Inc. - Business segments • 86.Pfizer Inc. - Key offerings • 87.Pfizer Inc. - Key customers • 88.Pfizer Inc. - Segment focus • 89.Sanofi - Overview • 90.Sanofi - Business segments • 91.Sanofi - Key offerings • 92.Sanofi - Key customers • 93.Sanofi - Segment focus • 94.Takeda Pharmaceutical Co. Ltd. - Overview • 95.Takeda Pharmaceutical Co. Ltd. - Product and service • 96.Takeda Pharmaceutical Co. Ltd. - Key offerings • 97.Takeda Pharmaceutical Co. Ltd. - Key customers • 98.Takeda Pharmaceutical Co. Ltd. - Segment focus • 99.Currency conversion rates for US$ • 100.Research Methodology • 101.Validation techniques employed for market sizing • 102Information sources • 103.List of abbreviations

AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd.